Table 3.
Efficacy of primary targeted therapy in patients with BRAF V600E mutation.
| Vemurafenib | Dabrafenib | Dabrafenib + Trametinib | |
|---|---|---|---|
| First-line | 9 | 2 | 5 |
| Further-line | 4 | 4 | 4 |
| Evaluable for response analysis | 13 | 5 | 9 |
| DCR | 12/13, 92.3% | 5/5, 100.0% | 9/9, 100.0% |
| PFS, months (95% CI) | 7.8 (3.9, 11.7) | 5.8 (0.2, 11.4) | 6.0 (5.0, 7.0) |
DCR, disease control rate; PFS, progression-free survival.